Green Cross Health Interim Results to 30 September 2025

Green Cross Health (NZX: GXH)
Half-Year Result Announcement for the unaudited six months ended 30 September 2025
GREEN CROSS HEALTH REPORTS HALF-YEAR RESULT
28 November 2025, AUCKLAND, NZ: Listed primary healthcare provider Green Cross Health, the
Group behind Unichem, Life Pharmacy and The Doctors, reported Operating Revenue of $264.4m
and Net Profit After Tax Attributable to Shareholders of $7.2m for the six months to 30 September
2025.
Result Summary
• Operating Revenue of $264.4m, up 2%
• Operating Profit (EBIT) of $17.5m, up 9%
• Net Profit After Tax Attributable to Shareholders of $7.2m, up 27%
• 3.0cps interim dividend declared, to be paid on 18 December 2025.
Group Commentary
Green Cross Health Group CEO Rachael Newfield, commented, “Over the last few months Green
Cross Health has worked closely with Health New Zealand to satisfy the conditions required to
become a Primary Health Organisation and is pleased to have received approval to commence
operations from 1 July 2026.
“While this year’s annual funding uplift for Medical is encouraging, Government investment in the
pharmacy sector continues to be inadequate. Community pharmacy is well-poised to tackle many
primary healthcare issues in New Zealand. The recent national measles outbreak saw Life and
Unichem pharmacies respond with a public outreach campaign which drove a significant increase
in measles vaccinations, demonstrating the sector’s importance in facilitating preventative care.
The Company calls for improved funding to pharmacies and expansion of pharmacists’ scope to
better utilise this extensive network of skilled clinicians and alleviate pressure on other areas of
the health system.”
Pharmacy Division
Revenue in Pharmacy was flat at $181.7m, with Operating Profit down 14% to $7.7m as margin
reduced due to a shift in sales mix from higher margin retail to lower margin dispensary. Unichem
and Life pharmacies administered over 304,000 vaccinations, a 6% increase on the prior period.
Same store prescriptions were in line with the prior period.
The expansion of the newly launched Care & Advice Health Hubs is progressing well, with the
division on track to achieve 200 branded pharmacies by year end. Extension of clinical services

continues, with Care & Advice Health Hub pharmacists now able to assess, treat and dispense
specified medication for 14 conditions, including Wegovy weight loss medication with patient
monitoring and follow-up.
The period was one of significant digital investment to support a seamless and engaging
omnichannel customer experience. A new Unichem Pharmacy website was launched, allowing
customers to browse stock availability online before visiting a store, click & collect products or
opt for home delivery. In addition, an upgraded online booking system was developed to
complement Care & Advice Health Hubs, giving customers a convenient way to connect with the
extended services now available through their local Unichem or Life pharmacy. The creation of a
new pharmacy app which is fully integrated with the booking system is well progressed. The app
will feature a modern and user-friendly interface to facilitate medication management and
service access, with launch planned for the second half of the year.
To grow within the beauty market, the Beauty by Life store concept expanded to two further
locations in the period, Life Queensgate and Life Albany. The refreshed layout modernises the
shopper experience and has enabled the division to secure new product brands for the Beauty by
Life stores as well as the wider network. The enhanced offer is supplemented by beauty services
to enrich customer experience and appeal to a broader market. Initial results are encouraging,
outperforming the historical format, and roll-out plans for further stores are under review.
Medical Division
Medical Revenue for the period grew 6% to $82.7m, with Operating Profit up 42% to $11.6m. Enrolled
patients within the portfolio of 65 medical centres totalled 414,500, the largest enrolled patient
base of any general practice group in New Zealand.
The 1 July 2025 Government funding boost for general practices is a significant step forward in
improving health outcomes for all patients. In addition, Health New Zealand granted approval to
Green Cross Health to establish a new Primary Health Organisation which will begin operating on 1
July 2026. This is a pivotal milestone for the Company and will strengthen frontline services by
optimising funding, eliminating administrative layers and enhancing the care provided to
communities across New Zealand.
During the period, The Doctors Online GP service was selected as one of the providers for the roll-
out of Health New Zealand’s new digital health service to improve timely access to healthcare. As
a result, online consultation volumes more than doubled compared to the same period last year,
with the service also assisting medical centres throughout the network to maintain timely
appointment availability for patients. Given the national shortage of general practitioners, the
team-based care model is being implemented across the network to enable patients to be connected

with the most appropriate clinician, increasing access by reducing patient wait times and lifting
operational efficiency.
Investment in technology, branding and site refurbishments also advanced in the period with the
launch of a refreshed website designed to improve user experience including streamlining key
functions such as new enrolments and appointment bookings. The Doctors app user base at 30
September 2025 totalled 148,000 registered users, an increase of 38,000 (+35%) since September
2024, booking an average of 23,000 appointments per month using the app. One practice rebranded
to The Doctors during the period while another commenced a substantial refurbishment and
expansion to double patient capacity in a larger, modernised clinical environment.
Outlook and Dividend
In the second half of the financial year the Company will be focused on preparing for the 1 July
2026 commencement of the newly approved Primary Health Organisation. Investment in
technology, targeted refurbishments and cost management will be a priority in both divisions. In
Pharmacy, investment in new products and extended services through the Care & Advice Health
Hubs will continue, along with advocating for required funding. The Board is cautiously optimistic
regarding the recovery of the New Zealand economy and the outlook for retail in 2026.
The Board has declared an interim dividend of 3.00 cents per share.
Contact:
Kalpana Goundar
kalpana.goundar@gxh.co.nz

Rachael Newfield
rachael.newfield@gxh.co.nz
About Green Cross Health
Green Cross Health (NZX: GXH) is a trusted New Zealand primary healthcare provider with
multidisciplinary healthcare teams working together to support healthier communities. Green
Cross Health is focused on creating sustainable healthcare solutions with positive outcomes and
experiences.
New Zealand owned and operated, Green Cross Health operates under branded groups Unichem,
Life Pharmacy and The Doctors, to provide support, care and advice to diverse New Zealand
communities.

Green Cross Health provides convenient access to professional healthcare with over 300 Unichem
and Life Pharmacies covering almost every New Zealand community, as well as 65 medical centres
caring for over 400,000 enrolled patients.

---

Green Cross Health Limited
Consolidated interim financial statements
Half year ended 30 September 2025

Contents
Page
Half-year financial statements
Consolidated interim statement of comprehensive income2
Consolidated interim statement of changes in equity3
Consolidated interim statement of financial position4
Consolidated interim statement of cash flows5
Notes to the consolidated financial statements6
Company Directory12
-
1-

Green Cross Health Limited
Consolidated interim statement of comprehensive income
For the six months ended 30 September 2025
Six months
ended
30 Sep 2025
Six months
ended
30 Sep 2024
(Unaudited)(Unaudited)
Note$'000$'000
Operating revenue3264,435259,877
Operating expenditure4.2(237,901)(234,979)
Depreciation and amortisation expense(2,647)(2,442)
Depreciation - leases(7,376)(7,155)
Share of equity accounted net earnings998802
Operating profit before interest and tax17,50916,103
Interest income227290
Interest expense(881)(1,170)
Interest expense - leases(4,220)(4,113)
Net interest expense(4,874)(4,993)
Profit before tax12,63511,110
Income tax expense(3,535)(3,021)
Profit for the period9,1008,089
Other comprehensive income for the period, net of tax
--
Total comprehensive income for the period
9,1008,089
Attributable to:
Shareholders of the Parent7,1855,647
Non-controlling interest1,9152,442
9,1008,089
Earnings per share:
Basic earnings per share (cents)5.003.93
Diluted earnings per share (cents)4.993.93
The accompanying Notes to the Consolidated Financial Statements on pages 6 to 11 form part of the consolidated interim
financial statements.
-2-

Green Cross Health Limited
Consolidated interim statement of changes in equity
For the six months ended 30 September 2025
Share capital
Share based
payment
reserves
Retained
earnings
Non-
controlling
interest
Total equity
Note$'000$'000$'000$'000$'000
Balance at 1 April 2024 (Restated)
(Audited)
9
90,94345066,32612,340170,059
Profit for the period--5,6472,4428,089
Total comprehensive income for the
period
--5,6472,4428,089
Distributions to non-controlling
interests
---(1,191)(1,191)
Impacts of other transactions--(1,003)(296)(1,299)
Dividends to shareholders7--(2,882)-(2,882)
Performance share rights vested150(150)---
Balance as at 30 September 2024
(Unaudited)
91,09330068,08813,295172,776
Balance at 1 April 2025 (Audited)91,09351574,97714,414180,999
Profit for the period--7,1851,9159,100
Total comprehensive income for the
period
--7,1851,9159,100
Distributions to non-controlling
interests
---(3,298)(3,298)
Impacts of other transactions--(2,692)(383)(3,075)
Dividends to shareholders7--(3,966)-(3,966)
Performance share rights charged to
SOCI
-212--212
Performance share rights vested150(150)---
Balance as at 30 September 2025
(Unaudited)
91,24357775,50412,648179,972
The accompanying Notes to the Consolidated Financial Statements on pages 6 to 11 form part of the consolidated interim
financial statements.
-3-

Green Cross Health Limited
Consolidated interim statement of financial position
As at 30 September 2025
As at
30 Sep 2025
As at
30 Sep 2024
As at
31 Mar 2025
(Unaudited)
(Restated)*
(Unaudited)(Audited)
Note$'000$'000$'000
ASSETS
Current assets
Cash and cash equivalents23,65328,85226,199
Trade and other receivables11,83512,7918,800
Contract assets13,98711,48913,924
Inventories34,04733,07533,167
Income taxes refundable2,0302,395-
Total current assets85,55288,60282,090
Non-current assets
Other receivables2,2952,7822,448
Property, plant and equipment22,25919,25619,740
Right-of-use assets95,59894,87696,279
Intangible assets166,221165,890165,947
Deferred tax asset12,53012,25812,275
Equity accounted group investments8,4767,2987,458
Total non-current assets307,379302,360304,147
Total assets392,931390,962386,237
LIABILITIES
Current liabilities
Trade payables and accruals71,17869,44965,076
Contract liabilities5,2715,8094,312
Income taxes payable--685
Borrowings1,8811,8221,855
Lease liabilities11,99312,37112,741
Total current liabilities90,32389,45184,669
Non-current liabilities
Borrowings23,73532,70322,581
Lease liabilities98,90196,03297,988
Total non-current liabilities122,636128,735120,569
Total liabilities212,959218,186205,238
Net assets
179,972172,776180,999
EQUITY
Share capital691,24391,09391,093
Share based payment reserve577300515
Retained earnings75,50468,08874,977
Total equity attributable to shareholders of the Parent167,324159,481166,585
Non-controlling interest12,64813,29514,414
Total equity
179,972172,776180,999
*Comparative information has been restated, refer Note 9.
The accompanying Notes to the Consolidated Financial Statements on pages 6 to 11 form part of the consolidated interim
financial statements.
-4-

Green Cross Health Limited
Consolidated interim statement of cash flows
For the six months ended 30 September 2025
Six months
ended
30 Sep 2025
Six months
ended
30 Sep 2024
(Unaudited)(Unaudited)
Note$'000$'000
Cash flows from operating activities
Dividends received720352
Receipts from customers261,329261,146
Interest received227256
Payments to suppliers and employees(234,169)(229,909)
Net income taxes(6,524)(6,578)
Net cash inflow from operating activities521,58325,267
Cash flows from investing activities
Purchases of property, plant, equipment and software intangibles(5,954)(2,192)
Acquisition of interests in equity accounted investments(233)-
Acquisition of interests in subsidiaries and non-controlling interests(4,232)(1,466)
Disposal of interests in subsidiaries and non-controlling interests3,080-
Net cash outflow from investing activities(7,339)(3,658)
Cash flows from financing activities
Proceeds from borrowings9,460540
Repayment of borrowings(8,280)(960)
Payment of lease liabilities(6,502)(6,082)
Interest expense(889)(1,222)
Interest expense - leases(4,220)(4,113)
Distributions to non-controlling interest(2,393)(1,568)
Dividend paid(3,966)(2,882)
Net cash outflow from financing activities(16,790)(16,287)
Net (decrease)/increase in cash and cash equivalents(2,546)5,322
Cash and cash equivalents at the beginning of the financial year26,19923,402
Cash acquired: business combinations-128
Cash and cash equivalents at the end of the period
23,65328,852
Reconciliation of closing cash and cash equivalents to the consolidated
interim statement of financial position:
Cash and cash equivalents
23,65328,852
Closing cash and cash equivalents
23,65328,852
The accompanying Notes to the Consolidated Financial Statements on pages 6 to 11 form part of the consolidated interim
financial statements.
-5-

Green Cross Health Limited
Notes to the consolidated financial statements
For the six months ended 30 September 2025
1 Reporting Entity
Green Cross Health Limited (the “Parent” or the "Company") is a New Zealand company registered under the Companies
Act 1993 and is an FMC entity for the purposes of the Financial Reporting Act 2013 and the Financial Markets Conduct
Act 2013. The Financial Statements have been prepared in accordance with these Acts. The Company is listed on the

New Zealand Stock Exchange ("NZX").
The consolidated interim financial statements of Green Cross Health Limited comprise the Parent, its subsidiaries, and its
interest in associates and joint ventures (together referred to as the “Group”).
2 Basis of preparation of financial statements
(a) Statement of compliance
The consolidated interim financial statements have been prepared in accordance with New Zealand Generally Accepted
Accounting Practice ("NZ GAAP"), NZ IAS 34 Interim Financial Reporting, and other applicable Financial Reporting
Standards as appropriate for profit oriented entities. These consolidated interim financial statements do not include all of
the information required for full annual financial statements and should be read in conjunction with the consolidated
financial statements of the Group as at and for the year ended 31 March 2025.
The consolidated interim financial statements for the six months ended 30 September 2025 and the comparative
information for the six months ended 30 September 2024 are unaudited.
The interim financial statements were approved by the Board of Directors on 27 November 2025.
(b) Basis of measurement
The interim financial statements of the Group are prepared under the historical cost basis unless otherwise noted within
the specific accounting policies below.
(c) Changes in accounting policy
The accounting policies applied by the Group in these consolidated interim financial statements are the same as those
applied by the Group in its consolidated financial statements for the year ended 31 March 2025.
(d) Comparatives
Comparative information has been restated for the prior period in relation to contract liabilities (refer Note 9).
(e) Significant estimates and judgments
In authorising the consolidated interim financial statements for the six months ended 30 September 2025, the Directors
have ensured that the specific accounting policies necessary for the proper understanding of the interim financial
statements have been disclosed, and that all accounting policies adopted are appropriate for the Group’s circumstances
and have been consistently applied throughout the period for all Group entities for the purposes of preparing the
consolidated interim financial statements.
Inherent in the application of certain accounting policies, judgments and estimates are required. The Directors note that
the actual results may differ from the judgments and estimates made.
The significant judgments made by management in applying the Group’s accounting policies and the key sources of
estimation uncertainty were the same as those described in the last annual financial statements.
-
6-

Green Cross Health Limited
Notes to the consolidated financial statements
For the six months ended 30 September 2025
(continued)
3 Segment reporting
The Group has two reportable segments: pharmacy services and medical services. The pharmacy services segment
provides retail and dispensary services and the medical services segment provides GP, nursing and urgent care services.
The Group's main operations are in the pharmacy industry providing pharmacy services through consolidated stores,
equity accounted investments and franchise stores. The medical services segment includes fully owned and equity
accounted medical centres, and support services provided to these medical centres.
Operating segments
Note
Pharmacy
services
Medical
servicesCorporateTotal
$'000$'000$'000$'000
30 September 2025 (Unaudited)
External revenues4.1181,74882,687-264,435
Cost of products sold(112,105)(96)-(112,201)
Employee benefit expense(40,231)(58,666)-(98,897)
Lease expenses(1,177)(292)-(1,469)
Other expenses(14,612)(8,903)(1,819)(25,334)
Depreciation and amortisation(1,676)(971)-(2,647)
Depreciation - leases(4,431)(2,945)-(7,376)
Share of equity accounted net earnings
187811-998
Segment profit
7,70311,625(1,819)17,509
Interest income227
Interest expense(881)
Interest expense - leases
(4,220)
Profit before tax12,635
Tax expense
(3,535)
Profit after tax9,100
Non-controlling interest
(1,915)
Net Profit attributable to the shareholders
of the Parent
7,185
Reportable segment assets275,404128,340(10,813)392,931
Reportable segment liabilities133,85789,915*(10,813)212,959
*Intersegmental elimination
-
7-

Green Cross Health Limited
Notes to the consolidated financial statements
For the six months ended 30 September 2025
(continued)
3 Segment reporting(continued)
Note
Pharmacy
services
Medical
servicesCorporateTotal
$'000$'000$'000$'000
30 September 2024 (Unaudited)
External revenues4.1182,21577,659-259,874
Other income3--3
Cost of products sold(110,267)(116)-(110,383)
Employee benefit expense(40,884)(57,075)-(97,959)
Lease expenses(1,618)(108)-(1,726)
Other expenses(14,881)(9,012)(1,018)(24,911)
Depreciation and amortisation(1,552)(946)-(2,498)
Depreciation - leases(4,208)(2,891)-(7,099)
Share of equity accounted net earnings
110692-802
Segment profit
8,9188,203(1,018)16,103
Interest income290
Interest expense(1,170)
Interest expense - leases
(4,113)
Profit before tax11,110
Tax expense
(3,021)
Profit after tax8,089
Non-controlling interest
(2,442)
Net Profit attributable to the shareholders
of the Parent
5,647
Reportable segment assets*277,270124,451(10,759)390,962
Reportable segment liabilities*134,70194,244**(10,759)218,186
*Comparative information has been restated, refer Note 9.
**Intersegmental elimination
-
8-

Green Cross Health Limited
Notes to the consolidated financial statements
For the six months ended 30 September 2025
(continued)
4 Operating performance
4.1 Revenue
The Group's operations and revenue streams are those described in the last annual financial statements. The Group's
revenue is derived from contracts with customers.
Six months
ended
30 Sep 2025
Six months
ended
30 Sep 2024
(Unaudited)(Unaudited)
Revenue from contracts with customers$'000$'000
Pharmacy retail and dispensary164,971164,945
Other pharmacy services16,77717,270
Medical services
82,68777,659
264,435259,874
Disaggregation of contract revenueReportable segments
Pharmacy
services
Medical
servicesTotal
$'000$'000$'000
Six months ended 30 September 2025 (Unaudited)
Timing of revenue recognition
Transferred at a point in time175,24137,859213,100
Transferred over time
6,50744,82851,335
181,74882,687264,435
Pharmacy
services
Medical
servicesTotal
$'000$'000$'000
Six months ended 30 September 2024 (Unaudited)
Timing of revenue recognition
Transferred at a point in time176,53735,648212,185
Transferred over time
5,67842,01147,689
182,21577,659259,874
4.2 Operating expenditure
Six months
ended
30 Sep 2025
Six months
ended
30 Sep 2024
(Unaudited)(Unaudited)
$'000$'000
Cost of products sold112,201110,383
Employee benefit expense98,89797,959
Lease expenses1,4691,726
Other expenses
25,33424,911
237,901234,979
-9-

Green Cross Health Limited
Notes to the consolidated financial statements
For the six months ended 30 September 2025
(continued)
5 Operating cash flow reconciliation
Six months
ended
30 Sep 2025
Six months
ended
30 Sep 2024
(Unaudited)(Unaudited)
$'000$'000
Profit for the period9,1008,089
Add/(deduct) non-cash items:
Depreciation, amortisation and impairment10,0239,597
Other non-cash items(3,161)(594)
Add/(deduct) changes in working capital:
Receivable and accruals movement(2,946)1,180
Inventory(880)(2,630)
Payable and accruals movement7,0617,955
Tax movement(2,715)(3,613)
Add items classified as cash flows from financing activities:
Interest expense8811,170
Interest expense - leases
4,2204,113
Net cash inflow from operating activities
21,58325,267
6 Shares on issue
As at
30 Sep 2025
As at
30 Sep 2024
As at
31 Mar 2025
(Unaudited)
(Restated)
(Unaudited)(Audited)
'000'000'000
Shares authorised and on issue
Opening number of shares143,603143,462143,462
Shares issued - fully paid114141141
Shares issued - partly paid---
Shares cancelled - partly paid
---
143,717143,603143,603
Performance share rights
607226440
144,324143,829144,043
Net tangible assets/(liabilities) per share (cents)^0.85(3.74)1.93
Net assets per share (cents)*125.23120.32126.04
^The calculation of net tangible assets / (liabilities) per share is based on net assets less deferred tax and intangible
assets and the closing number of ordinary shares at the end of the period.
*The calculation of net assets per share is based on net assets and the closing number of ordinary shares at the end of
the period.
Performance share rights of 607,074 are on issue as at 30 September 2025. These were issued to some senior
executives on 26 June 2023, 27 November 2024 and 31 July 2025.
-
10-

Green Cross Health Limited
Notes to the consolidated financial statements
For the six months ended 30 September 2025
(continued)
7 Dividends
On 23 June 2025 Green Cross Health Limited paid a final dividend for the March 2025 year of 2.75 cents per qualifying
ordinary share to shareholders, which was fully imputed at 28%.
Six months
ended
Six months
endedYear ended
30 Sep 202530 Sep 202431 Mar 2025
cents per
share
cents per
share
cents per
share
Dividends per share
2.752.004.50
8 Subsequent events
On 27 November 2025, Green Cross Health Limited declared an interim dividend of 3.00 cents per qualifying ordinary
share amounting to $4.3m, which will be fully imputed at 28%. The dividend record date is 5 December 2025 and payment
will occur on 18 December 2025.
No adjustment is required to these consolidated interim financial statements in respect of this event.
9 Prior period restatement
As reported in 31 March 2025, an error was identified in determining the value of contract liabilities following the
enhancement of reporting. The error related to the activity data used in the calculation of the contract liabilities being
overstated. This resulted in a prior period restatement to adjust the balance of contract liabilities.
The following table reconciles the impact on key line items in the Group's statement of financial position from
restatements.
As at
31 March 2024
As at
31 March 2024
AuditedAdjustmentsRestated
$'000$'000$'000
Consolidated statement of financial position
Income taxes refundable404(404)-
Others
382,882-382,882
Total assets
383,286(404)382,882
Total payables and accruals72,095(4,792)67,303
Income taxes payable-937937
Others
144,583-144,583
Total liabilities
216,678(3,855)212,823
Retained earnings62,8753,45166,326
Others
103,733-103,733
Total equity
166,6083,451170,059
-11-

Green Cross Health Limited
Company Directory
BoardK Ellis
Independent Chair
J A Bagnall
Non-Executive Director
J B Bolland
Non-Executive Director
C M Brockliss
Non-Executive Director
P M Merton
Non-Executive Director
K A Orr
Independent Director
C J Treneman
Independent Director
OfficersRachael Newfield
Group CEO
Kalpana Goundar
CFO/Company Secretary
Registered officeGreen Cross Health Limited
Millenium Centre
Ground Floor, Building B
602 Great South Road
Ellerslie. Auckland 1051
Telephone: +64 9 571 9080
Share registerComputershare Investor Services Limited
Private Bag 92119
Auckland 1142
Level 2, 159 Hurstmere Road
Takapuna, Auckland 0622
Managing your shareholding online:
To change your address, update your payment instructions and to view your
registered details including transactions, please visit:
www.investorcentre.com
General enquiries can be directed to:
enquiry@computershare.co.nz
Telephone: +64 9 488 8700
Facsimile: +64 9 488 8787
Please assist our registrar by quoting your CSN or shareholder number.
AuditorKPMG
KPMG Centre
18 Viaduct Harbour Avenue
Auckland Central
Auckland 1010
-12-

Green Cross Health Limited
Company Directory(continued)
BankersBank of New Zealand
80 Queen Street
Auckland Central
Auckland 1010
Bank of China
66 Wyndham Street
Auckland Central
Auckland 1010
Investor relationsFor investor relations enquiries:
Phone: 09 571 9088
Email: investorrelations@gxh.co.nz
Websiteswww.greencrosshealth.co.nz
www.lifepharmacy.co.nz
www.unichem.co.nz
www.livingrewards.co.nz
www.pilldrop.co.nz
www.thedoctors.co.nz
www.thedoctorsonline.co.nz
-13-

---

Results announcement 28/11/2025
(for Equity Security issuer/Equity and Debt Security issuer)


Results for announcement to the market
Name of issuer Green Cross Health Limited (GXH)
Reporting Period 6 months to 30 September 2025
Previous Reporting Period 6 months to 30 September 2024
Currency New Zealand Dollars
Amount (000s) Percentage change
Revenue from continuing
operations
$264,435 +1.8%
Total Revenue $264,435 +1.8%
Net profit/(loss) from
continuing operations
$7,185* +27.2%
Total net profit/(loss) $7,185* +27.2%
Interim Dividend
Amount per Quoted Equity
Security
$0.03000000
Imputed amount per Quoted
Equity Security
$0.01166667
Record Date 05/12/2025
Dividend Payment Date 18/12/2025
Current period Prior comparable period
Net tangible assets per
Quoted Equity Security (in
dollars and cents per
security)
$0.01 ($0.04)
A brief explanation of any of
the figures above necessary
to enable the figures to be
understood
Due to the nature of the Company’s business, intangible assets
are a major component of total assets. Net assets per quoted
equity security are $1.25 (30 September 2024: $1.20)
The prior comparable period net tangible assets per quoted
equity security detailed in the above table and the net assets per
quoted equity security in the above comment are based on 30
September 2024 restated figures.
Please refer to the attached unaudited Financial Statements for
the 6 months ended 30 September 2025.
* attributable to shareholders
Authority for this announcement
Name of person

authorised
to make this announcement
Kalpana Goundar - CFO
Contact person for this
announcement
Kalpana Goundar - CFO

Contact phone number 09 571 9080
Contact email address kalpana.goundar@greencrosshealth.co.nz
Date of release through MAP

28/11/2025

Unaudited financial statements accompany this announcement.

---

Distribution Notice 28/11/2025



Section 1: Issuer information
Name of issuer Green Cross Health Limited
Financial product name/description Ordinary Shares
NZX ticker code GXH
ISIN (If unknown, check on NZX
website)
NZBDOE0001S8
Type of distribution
(Please mark with an X in the
relevant box/es)
Full Year Quarterly
Half Year X Special
DRP applies No
Record date 05/12/2025
Ex-Date (one business day before the
Record Date)
04/12/2025
Payment date (and allotment date for
DRP)
18/12/2025
Total monies associated with the
distribution
1

$4,311,501
Source of distribution (for example,
retained earnings)
Retained Earnings
Currency New Zealand Dollars
Section 2: Distribution amounts per financial product
Gross distribution
2
$0.04166667
Gross taxable amount
3
$0.04166667
Total cash distribution
4
$0.03000000
Excluded amount (applicable to listed
PIEs)
N/A
Supplementary distribution amount $0.00529412
Section 3: Imputation credits and Resident Withholding Tax
5

Is the distribution imputed

Fully imputed


1
Continuous issuers should indicate that this is based on the number of units on issue at the date of the form
2
“Gross distribution” is the total cash distribution plus the amount of imputation credits, per financial product, before the deduction of
Resident Withholding Tax (RWT).
3
“Gross taxable amount” is the gross distribution minus any excluded income.
4
“Total cash distribution” is the cash distribution excluding imputation credits, per financial product, before the deduction of RWT.
This should include any excluded amounts, where applicable to listed PIEs.
5
The imputation credits plus the RWT amount is 33% of the gross taxable amount for the purposes of this form. If the distribution is
fully imputed the imputation credits will be 28% of the gross taxable amount with remaining 5% being RWT. This does not constitute
advice as to whether or not RWT needs to be withheld.

If fully or partially imputed, please
state imputation rate as % applied
6

28%
Imputation tax credits per financial
product
$0.01166667
Resident Withholding Tax per
financial product
$0.00208333
Section 4: Distribution re-investment plan (if applicable)
DRP % discount (if any)
N/A
Start date and end date for
determining market price for DRP
N/A N/A
Date strike price to be announced (if
not available at this time)
N/A
Specify source of financial products to
be issued under DRP programme
(new issue or to be bought on market)
N/A
DRP strike price per financial product
N/A
Last date to submit a participation
notice for this distribution in
accordance with DRP participation
terms
N/A
Section 5: Authority for this announcement
Name of person

authorised to make
this announcement
Kalpana Goundar – CFO
Contact person for this
announcement
Kalpana Goundar - CFO
Contact phone number 09 571 9080
Contact email address kalpana.goundar@greencrosshealth.co.nz
Date of release through MAP

28/11/2025






6
Calculated as (imputation credits/gross taxable amount) x 100. Fully imputed dividends will be 28% as a % rate applied.